Posted by Michael Wonder on 07 May 2020
Dr. Reddy's Laboratories received approval for their NDA, Elyxyb (celecoxib 25 mg/mL oral solution) in the U.S
6 May 2020 - Dr. Reddy’s Laboratories today announced approval of Elyxyb (celecoxib 25 mg/mL oral solution) by the U.S. FDA.
Elyxyb (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults.
Elyxyb is the latest product emerging from Dr. Reddy’s portfolio of successful acute migraine treatments. The company is working to commercialise this product through partners.
